Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-09-07
2009-11-24
Huynh, Phuong (Department: 1644)
Chemistry: molecular biology and microbiology
Vector, per se
C514S04400A, C536S023700
Reexamination Certificate
active
07622297
ABSTRACT:
The α antigen-encoding gene and the α antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of atopic diseases such as atopic dermatitis, asthma, allergic rhinitis, and allergic conjunctivitis, and more broadly allergic diseases.
REFERENCES:
patent: 6498148 (2002-12-01), Raz
patent: 7524675 (2009-04-01), Yasutomi et al.
patent: 4422859 (1996-11-01), None
patent: 400973 (1990-05-01), None
patent: 2-308793 (1990-12-01), None
patent: WO 98/26790 (1998-06-01), None
patent: WO 98/44096 (1998-10-01), None
Verma et al, Nature 389: 239-242, Sep. 1997.
Reyes-Sandoval et al, Curr Mol Med 1(2):217-43, May 2001.
Tuteja et al, Crit Rev Biochem Mol Biol 34(1):1-24, 1999.
Thomas et al, Nature Reviews 4: 346-358, May 2003.
D. Jullien, et al, “Alpha Interferon Treatment in Atopic Dermatitis”, Acta Derm Venereol (Stockh), 73, pp. 130-132 (1993).
B. Windelborg Nielsen, et al, “Interferon therapy for atopic dermatitis reduces basophil histamine release, but does not reduce serum IgE or eosinophilic proteins”, Allergy, 49, pp. 120-128 (1994).
H. Tasaka, et al, “Specificity and Distribution of Alpha Antigens ofMycobacterium KansasiiandMycobacterium marinum” Am. Reo. Respire. Dis., 130, pp. 647-649 (1984).
H. Tasaka, et al, Specificity and Distribution of Alpha Antigens ofMycobacterium avium-intracellulare, Mycobacterium scrofulaceum, and Related Species of Mycobacteria, Am. Reo. Respir. Dis., 132, pp. 173-174 (1985).
H. Kitaura, et al, “Cloning, Sequencing and Expression of the Gene for Antigen fromMycobacterium Intracellulareand use of PCR for the Rapid Identification ofMycobacterium Intracellulare”, Biochemical and Biophysical Reserch Communications, vol. 196, No. 3, pp. 1466-1473 (1993).
C.E.H. Grattan; et al, “Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria”, British Journal of Dermatology, 143, pp. 365-372 (2000).
K. M. McAveney, et al, “Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy”, Cancer Immunol Immunother, 39, pp. 401-406 (1994).
A. Thanhäuser, et al, “The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells”, Cancer Immunol Immunother, 40, pp. 103-108 (1995).
H. Niwa, et al, Efficient selection for high-expression transfectants with a novel eukaryotic vector, Gene, 108, pp. 193-200 (1991).
H. Tasaka, et al, “Purification and Antigenic Specificity of Alpha Protein (Yoneda and Fukui) fromMycobacterium tuberculosisandMycobacterium intracellulare”, Hiroshima Journal of Medical Sciences, vol. 32, No. 1, pp. 1-8 (1983).
M. Borremans, et al, “Cloning, Sequence Determination, and Expression of a 32-Kilodalton-Protein Gene ofMycobacterium tuberculosis”, Infection and Immunity, vol. 57, No. 10, pp. 3123-3130 (1989).
K. Matsuo, et al, “Cloning and Expression of the Gene for the Cross-Reactive α Antigen ofMycobacterium kansasii”, Infection and Immunity, vol. 58, No. 2, pp. 550-556 (1990).
J. Content, et al, “The Genes Coding for the Antigen 85 Complexes ofMycobacterium tuberculosisandMycobacterium bovisBCG are Members of a Gene Family: Cloning, Sequence Determination, and Genomic Organization of the Gene Coding for Antigen 85-C ofM. tuberculosis”, Infection and Immunity, vol. 59, No. 9, pp. 3205-3212 (1991).
K. Huygen, et al, “Spleen Cell Cytokine Secretion inMycobacterium bovisBCG-Infected Mice”, Infection and Immunity, vol. 60, No. 7, pp. 2880-2886 (1992).
N. Ohara, et al, “Cloning and Sequencing of the Gene for α Antigen fromMycobacterium aviumand Mapping of B-Cell Epitopes”, Infection and Immunity, vol. 61, No. 4, pp. 1173-1179 (1993).
A. Mori, et al, “Control of IL-5 production by human helper T cells as a treatment for eosinophilic inflammation: Comparison of in vitro and in vivo effects between selective and nonselective cytokine synthesis inhibitors”, J. Allergy Clin Immunol, vol. 106, No. 1, Part 2 pp. S58-S64 (2000).
A. Torrelo, et al, “Interferon therapy for chronic urticaria”, Journal of the American Academy of Dermatology, vol. 32, No. 4, pp. 684-685 (1991).
K. Matsuo, et al, “Cloning and Expression of theMycobacterium bovisBCG Gene for Extracellular α Antigen”, Journal of Bacteriology, vol. 170, No. 9, pp. 3847-3854 (1988).
K. Yamanaka, et al, “Skin-Specific Caspase-l-Transgenic Mice Show Cutaneous Apoptosis and Pre-Endotoxin Shock Condition with a High Serum Level of IL-18”, The Journal of Immunology, vol. 165, pp. 997-1003 (2000).
H. G. Wiker, et al, “The Antigen 85 Complex: a Major Secretion Product ofMycobacterium tuberculosis”, Microbiological Reviews, vol. 56, No. 4, pp. 648-661 (1992).
J. E. R. Thole, et al, “Molecular and immunological analysis of a fibronectin-binding protein antigen secreted byMycobacterium leprae”, Molecular Microbiology, 6(2), pp. 153-163 (1992).
T. Yoshimoto, et al, “IL-18 induction of IgE: dependence on CD4+T cells, IL-4 and STAT6”, Nature Immunology, vol. 1, No. 2, pp. 132-137 (2000).
Editorial “Taming tuberculosis—again”, Nature Structural Biology, vol. 7, No. 2, pp. 87-88 (2000).
M. Furue, “Cytokine, Adhesion Molecules and Cutaneous Lymphocyte-Associated Antigen in Atopic Dermatitis”, Progress in Medicine, vol. 17, No. 1, pp. 19-24 (1997).
N. Wada, et al, “Long-Lasting Immune Response Induced by Recombinant Bacillus Calmette-Guérin (BCG) Secretion System”, Scand. J. Immunol. 43, pp. 202-209 (1996).
J. T. Belisle, et al, “Role of the Major Antigen ofMycobacterium tuberculosisin Cell Wall Biogenesis”, Science, vol. 276, pp. 1420-1422 (1997).
T. Matsunaga, et al, “Current conception of topic dermititas”, Igaku no Ayumi (Journal of Clinical and Experimental Medicine), 180(1), pp. 51-55 (1997).
C. B. Scanga, et al, “Development of an Asthma Vaccine—Research into BCG”, Drugs, 59(6); pp. 1217-1221 (2000).
M. Kumar, et al, “A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthese in BALB/c mice”, Immunology, 97, pp. 515-521 (1999).
P. D. Arkwright, et al, “Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease”, J Allergy Clin Immunol, vol. 107, No. 3, pp. 531-534 (2001).
Ngo et al, The Protein Folding Problem and Tertiary Structure Prediction, pp. 491-495 (1994).
Stryer et al, in Biochemistry, Third Edition, W H Freeman Company, New York, pp. 31-33 (1998).
Naito et al, Vaccine 18: 795-798, Jan. 2000.
Launois et al, Infection and Immunity 62(9):3679-3687, Sep. 1994.
Webster's II New Riverside University Dictionary, p. 933 (1984).
Mason et al., Molecular Endocrinology 8(3): 325-332, 1994.
Alm et al., Allergy 53(5): 537, May 1998.
Dalton et al., J Royal Society of Med 91: 133-134, 1998.
Spiegelberg et al., Pediatr Pulmonol Suppl 18: 118-21, 1999.
Fujieda et al., Am J Repir Crit Care Med 160: 2056-206, 1999.
Raz et al., Proc Natl. Acad. Sci. USA 93: 5141-5145, May 1996.
Lozes et al., Vaccine 15(8): 830-833, 1997.
Joel N. Kline, et al., “Cutting Edge: Modulation of Airway Inflammation by CpG Oligodeoxynucleotides in a Murine Model of Asthma”, Immunology, 160: 2555-2559, 1998.
Evelyne Lozes, et al., “Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex”, Vaccine, 15(8): 830-833, 1997.
C.C. Wang, et al., “Inhi
Mizutani Hitoshi
Yasutomi Yasuhiro
Huynh Phuong
Maruho Co. Ltd.
Sughrue & Mion, PLLC
LandOfFree
Pharmaceutical use of α antigen or α antigen gene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical use of α antigen or α antigen gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical use of α antigen or α antigen gene will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4114047